Business Wire

Exscientia Business Update for Third Quarter 2021

Share

Exscientia (Nasdaq: EXAI):

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211117006300/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: Business Wire)

Recent advancements in the Company’s pipeline, collaborations and operations as well as financial results for the third quarter ended September 30, 2021 are summarised below. In addition, Exscientia will host a conference call on Thursday, November 18 at 1:30 p.m. GMT / 8:30 a.m. ET to provide detail on the business models underlying the Company’s pipeline of more than 25 programmes.

Highlights

Leveraging deep learning on patient tissue samples at scale to transform target discovery and patient selection

- Expanded investigation of patient tissue models in solid tumours, including ongoing analysis of EXS-617 in ovarian and breast cancer models

- Published EXALT-1 clinical trial results in Cancer Discovery that highlighted benefit of the first AI-supported functional precision medicine platform to guide treatment selection and improve outcomes in patients with advanced haematological cancer

- Completed acquisition of Allcyte, integrating leading tissue platform into Exscientia’s end-to-end drug discovery operations

Pipeline progress marked by candidate nomination, significant expansion of existing collaborations

- Partnered programmes

  • Expanded Bristol Myers Squibb collaboration to include potential targets across immunology and oncology; potential deal value beyond $1.3 billion
    • BMS in-licensed first candidate from original 2019 collaboration, a potential first-in-class immunology medicine, triggering $20.0 million option exercise fee

- Co-owned programmes

  • EXS-617: development candidate nominated for CDK7 inhibitor from expanded joint venture with GT Apeiron; additional translational data anticipated 1H 2022
  • First two targets selected in EQRx joint venture

- Wholly and majority owned programmes

  • EXS-21546: Phase 1 data for A2a antagonist in high adenosine signature cancers expected 1H 2022; translational research programmes for patient selection ongoing
  • Entered into third collaboration with Bill & Melinda Gates Foundation that added portfolio of up to five antiviral small molecule drug candidates and accelerated development of SARS-CoV-2 lead programme

Strengthened balance sheet providing several years of cash runway to deliver AI-designed molecules and accelerate pipeline growth

- Expect between $75.0-$85.0 million in cash inflows from collaborations for full year 2021

- In October, closed $510.4 million gross aggregate financing, consisting of $350.4 million gross proceeds from upsized initial public offering and $160.0 million gross proceeds from concurrent private placement

- Cash at the end of the third quarter 2021, adjusted to include the net proceeds from the initial public offering completed on October 5, 2021, was $783.7 million

Expanding drug discovery and automation laboratories to scale capacity and operations

- Opened 21,000-square foot expansion of facilities at Oxford Science Park

- Building 26,000-square foot laboratory in Milton Park, Oxfordshire focused on the automation of chemistry and biology to accelerate drug discovery

- Building 50,000-square foot precision medicine centre of excellence in Vienna, Austria

- Added to U.S. footprint with expansion in Miami, opening of office in Boston, and key hires in strategic operations, technology and chemistry

“Exscientia is leading the modernisation of how new medicines are created by using AI in each step of discovery and development. Demonstrating our unique translational capabilities, we recently published groundbreaking results showing our AI precision medicine platform can improve outcomes for cancer patients. We have also propelled our pipeline through substantial investment in our own new medicine programmes, significantly expanded our relationship with Bristol Myers Squibb, and added a portfolio of pandemic preparedness antivirals to our work with the Bill and Melinda Gates Foundation. Finally, we began expanding our labs, investing in scaling our precision medicine platform and automated synthesis and screening,” said Andrew Hopkins, DPhil., Exscientia’s founder and CEO. “We have incredible momentum, and with our solid balance sheet post IPO, we will continue investing in innovation that can enable the rapid translation of today’s most promising science into tomorrow’s best possible medicines.”

Investor Call and Webcast Information

Exscientia will host a conference call on November 18 at 1:30 p.m. GMT / 8:30 a.m. ET. A webcast of the live call can be accessed by visiting the “Investors and Media” section of the Company’s website at investors.exscientia.ai. Alternatively, the live conference call can be accessed by dialing +1 760 294 1674 (U.S.), +44 203 059 5869 (U.K.), +44 203 059 8128 (International) and mentioning Exscientia. A replay will be available for 90 days under “Events and Presentations” in the “Investors and Media” section of the Exscientia website.

Third Quarter Financial Results

For the convenience of the reader, the Company has translated pound sterling amounts to U.S. dollars at the rate of £1.000 to $1.347, which was the noon buying rate of the Federal Reserve Bank of New York on September 30, 2021.

Revenue: Revenue for the nine months ended September 30, 2021, was $31.3 million, an increase of $23.6 million compared to the nine months ended September 30, 2020, primarily due to the achievement of the opt-in milestone on the first candidate in-licensed on Exscientia’s collaboration with BMS.

R&D and cost of drug discovery: Due to various collaboration structures, R&D expenses may be included under multiple accounting line items. The tables below show how these expenses are separated across the accounting categories.

Three months ended September 30, 2021 ($ millions):

 

COGS

R&D

Share of

JV loss

Total

Partnered Programmes

6.5

––

––

6.5

Co-owned Programmes

––

1.0

0.3

1.4

Internal Pipeline and Technology Development

––

16.4

––

16.4

Total

6.5

17.4

0.3

24.2

Nine months ended September 30, 2021 ($ millions):

 

COGS

R&D

Share of

JV loss

Total

Partnered Programmes

16.6

––

––

16.6

Co-owned Programmes

––

1.8

1.3

3.1

Internal Pipeline and Technology Development

––

32.3

––

32.3

Total

16.6

34.1

1.3

52.0

General and administrative expenses: G&A expenses for the nine months ended September 30, 2021 were $26.1 million, or 34% of total operating expenses. For the nine months ended September 30, 2021, G&A expenses grew by $20.2 million compared to the nine months ended September 30, 2020, primarily associated with both an expansion of internal capabilities as well as transaction-related professional services.

Financial Outlook for 2021 & 2022

For the first three quarters of 2021, Exscientia announced three new partnerships and received $65.4 million cash inflows from its collaborations. The Company expects to receive a total of $75.0-$85.0 million by year-end 2021, and anticipates 2022 cash inflows from collaborations will exceed 2021 cash inflows from collaborations. Exscientia expects to end 2021 with cash and cash equivalents between $745.0-$755.0 million.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited)
(in £ millions, except per share data)

 

Three months ended

September 30,

Nine months ended

September 30,

 

2021

2020

2021

2020

Revenue

17.6

1.0

23.2

5.7

Cost of sales

(4.8)

(3.3)

(12.3)

(10.3)

Research and development expenses

(12.9)

(2.9)

(25.3)

(7.2)

General and administrative expenses

(8.6)

(1.5)

(19.4)

(4.4)

Operating expenses

(26.3)

(7.7)

(57.0)

(21.8)

Foreign exchange gains/(losses)

1.7

(2.4)

(1.2)

(0.9)

Other income

1.8

0.4

3.0

0.8

Operating loss

(5.3)

(8.7)

(32.0)

(16.2)

Finance income/(expense)

(0.1)

(0.0)

(0.1)

0.0

Share of loss on joint ventures

(0.2)

(0.4)

(1.0)

(0.9)

Loss on derivative financial instruments

(1.4)

––

––

––

Loss before taxation

(6.9)

(9.2)

(33.1)

(17.0)

Income tax benefit

1.9

0.8

4.0

1.5

Loss for the period

(5.1)

(8.4)

(29.1)

(15.6)

Net loss per share

(0.06)

(0.08)

(0.32)

(0.15)

CONSTANT CURRENCY CONVERSION (unaudited)
(in $ millions, except per share data, at the rate of £1.000 to $1.347)

 

Three months ended

September 30,

Nine months ended

September 30,

 

2021

2020

2021

2020

Revenue

23.8

1.3

31.3

7.7

Cost of sales

(6.5)

(4.5)

(16.6)

(13.8)

Research and development expenses

(17.4)

(3.8)

(34.1)

(9.7)

General and administrative expenses

(11.6)

(2.0)

(26.1)

(6.0)

Operating expenses

(35.5)

(10.4)

(76.8)

(29.4)

Foreign exchange gains/(losses)

2.2

(3.2)

(1.7)

(1.2)

Other income

2.4

0.5

4.0

1.1

Operating loss

(7.1)

(11.7)

(43.1)

(21.8)

Finance income/(expense)

(0.1)

(0.0)

(0.2)

0.0

Share of loss on joint ventures

(0.3)

(0.6)

(1.3)

(1.2)

Loss on derivative financial instruments

(1.8)

––

––

––

Loss before taxation

(9.3)

(12.3)

(44.6)

(22.9)

Income tax benefit

2.5

1.1

5.3

2.0

Loss for the period

(6.8)

(11.3)

(39.3)

(21.0)

Net loss per share

(0.08)

(0.11)

(0.43)

(0.20)

About Exscientia

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our pipeline of internal and partnered programmes demonstrates our ability to rapidly translate scientific concepts into precision-designed therapeutic candidates, with more than 25 projects advancing, including the first three AI-designed drug candidates to enter Phase 1 clinical trials.

Exscientia has offices in Oxford, Vienna, Dundee, Miami, Boston, and Osaka. For more information visit us on https://www.exscientia.ai or follow us on Twitter @exscientiaAI.

Forward-Looking Statements

This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of development of candidate molecules, timing and progress of, and data reported from, clinical trials of Exscientia’s product candidates, and Exscientia’s expectations regarding its projected revenue and cash runway. Any statement describing Exscientia’s goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to the impact that the COVID-19 pandemic could have on the Company’s business, and including the scope, progress and expansion of Exscientia’s product development efforts; the initiation, scope and progress of Exscientia’s and its partners’ clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; and those inherent in the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia’s Registration Statement on Form F-1, filed with the Securities and Exchange Commission (SEC) on September 10, 2021, as amended (File No. 333-259431), and other filings that Exscientia makes with the SEC from time to time (which are available at http://www.sec.gov), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia’s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia’s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Investors:
Sara Sherman
investors@exscientia.ai

Media:
Amanda Galgay
media@exscientia.ai

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sunny Varkey Launches Tmrw, a New Learning Operating System (LearnOS) for Global Education to Bring a Quality Education Within Reach of Every Child7.12.2021 17:48:00 EET | Press release

Tmrw, a new and scalable Learning Operating System (LearnOS) for global education with a mission to help bring a quality education to every child, was launched this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005768/en/ Sunny Varkey, Chairman and Founder of Tmrw (Photo: Business Wire) Its interoperable All-In-One Integrated Platform is built to be accessible and affordable for Government funded schools operating in both the developed and developing world settings. In particular, it seeks to reach all students irrespective of their background or their ability to pay. It is designed to cater to the needs of every curriculum, context and mode of learning, whether brick and mortar, virtual or blended. Tmrw’s vision over time is to underpin learning, teaching, and the operational needs of K12 education, higher education and life-long learning. Sunny Varkey, who also founded the Global Teacher Prize, has ensured th

Nexo Expands Institutional Access to Crypto in Collaboration with Fidelity Digital Assets7.12.2021 17:30:00 EET | Press release

Nexo , the leading regulated institution for digital assets, today announced its collaboration with Fidelity Digital AssetsSM, a leading institutional focused execution and custody services platform provider, to revolutionize institutional access to digital assets by together offering best-in-class custodial and lending services, including the launch of innovative institutional-focused products. Nexo, a pioneer of cryptocurrency-collateralized credit, and Fidelity Digital Assets as custodian and collateral agent, will develop a comprehensive product suite and compliant infrastructure for institutional investors seeking exposure to digital assets. As a first step, the collaboration with Fidelity Digital Assets will expand Nexo’s ability to service and enhance its growing portfolio of assets under management and will provide an additional custody layer to Nexo’s military-grade security infrastructure. This latest development gives institutional investors who currently custody their digit

Percona Platform Unifies Open Source Databases, Supports Private Database-as-a-Service Deployments7.12.2021 17:20:00 EET | Press release

Percona, a leader in open source database software and services, today announced Percona Platform to bring together database distributions, support expertise, services, management and automated insights into a single product. Building on the company’s expertise with databases including MySQL, PostgreSQL and MongoDB, the new Percona Platform will simplify how users monitor, manage and optimize their database instances across any infrastructure. In addition, Percona Platform will enable developers and database administrators to run their own private Database-as-a-Service (DBaaS) instances. This launch will preview the Percona Platform, allowing users to unify the entire database experience from packages and backup to monitoring and management, with general availability in early 2022. Percona brings together distributions of MySQL, PostgreSQL and MongoDB including a range of open source tools for data backup, availability and management. It also includes Percona Monitoring and Management

Zencity Accelerates Collaboration Between Communities and Local Governments by Acquiring Civil Space7.12.2021 17:16:00 EET | Press release

Zencity, the leading global community engagement technology platform for local governments, announced the acquisition of cutting edge digital engagement startup Civil Space, based in Vancouver, Canada. The deal immediately adds to Zencity’s powerful suite the capability to create and capture deep, meaningful, equitable, two-way conversations between governments and their residents. With its acquisition of Civil Space, Zencity emerges as the most effective, inclusive and wide-reaching community engagement platform available for local governments, built around two core principles: Lowering the barriers to participation by meeting residents where they are and hearing many more voices; and Making it easier for governments to turn the resulting, broadened community input into action. The combination of Zencity’s analysis of broad community input with Civil Space’s direct engagement platform will enable local leaders to further enhance the feedback they are leveraging. The information will b

MCR Acquires Cloud-Based Hotel Management Platform Optii7.12.2021 17:00:00 EET | Press release

MCR, the 4th-largest hotel owner-operator in the United States and one of Fast Company’s 10 Most Innovative Travel Companies of 2020, has acquired Optii, the only predictive, cloud-based technology for improved hotel operations. Optii will continue to be a standalone company with its existing management team of CEO Katherine Grass, Founder and CSO Soenke Weiss and CRO Deborah Pevenstein. MCR’s portfolio of 140 branded and independent hotels will be arms-length customers of Optii, which will continue to offer its product to forward-thinking hotel companies. No data will be shared with MCR. MCR will mobilize its 4,000 hotel team members — who will utilize Optii for 20,000 guestrooms per day — to push for innovative product enhancements. Stayntouch property management system software, another standalone company owned by MCR, will integrate with Optii. A data-driven platform powered by artificial intelligence, Optii has revolutionized housekeeping technology, optimizing labor and cleaning

Alation Forges Strategic Partnerships With Bigeye and Soda7.12.2021 17:00:00 EET | Press release

Alation, Inc., the leader in enterprise data intelligence solutions, today announced formal partnership agreements with Bigeye and Soda, leading data observability vendors. The partnerships provide customers with the choice to select the best data observability partner for their organisation’s needs. Alation’s active data governance helps organisations drive data culture by providing all data users, regardless of technical skillset, with access to quality data. Bigeye’s data observability platform helps detect data quality issues and ensures reliable data pipelines. Soda’s data observability platform allows teams to discover, prioritise, and collaboratively resolve data issues. The platforms are invaluable for alerting technical users to deeper data quality issues, such as the trustworthiness of the data or its usability. Alation’s integrations with Bigeye and Soda provide all data consumers, from business users to data scientists, with a single-pane-of-glass view into the trustworthin

Acadia and Capitolis Launch SA-CCR Optimization Service7.12.2021 16:30:00 EET | Press release

Acadia, the leading industry provider of integrated risk management services for the derivatives community, and Capitolis, the leading SaaS platform that drives financial resource optimization for capital markets, today announced the launch of SA-CCR Optimization. SA-CCR Optimization will bring considerable cost savings to firms subject to the Standard Approach to Counterparty Credit Risk (SA-CCR) regulations, focusing on specific FX products such as FX forwards, options, deliverable swaps and cross-currency swaps. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005660/en/ With SA-CCR Optimization, banks and participating financial institutions provide trade data, which Acadia and Capitolis process and use to generate a series of FX transactions that reduce capital requirements, leaving each client’s net FX risk profile largely unchanged. “The newest wave of capital regulation is pushing firms to be more mindful of capi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom